BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization
VANCOUVER, BC / ACCESS Newswire / May 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its first national level patent filing has been accepted by the Eurasian Patent Organization (EAPO). The EAPO has confirmed the Company‘s core patent claims, namely: novelty, inventive step, and industrial applicability.
BioNxt's flagship patent filing, which received a positive international examination report from the European Patent Office, reported September 9, 2024, is a comprehensive patent application for sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. This patent family provides numerous proprietary product development and commercialization opportunities, including BioNxt's lead product, BNT23001, a sublingual thin-film formulation of Cladribine for the treatment of multiple sclerosis (MS).
The EAPO covers Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, and Turkmenistan. These countries are the members of the Eurasian Patent Convention (EAPC), which provides a single, harmonized patent application process and regulator for the region. The EAPO grants Eurasian patents that are valid in all eight member states.
BioNxt continues to advance the nationalization phase of the patent protection process at the European Patent Office and Eurasian Patent Organization, as well as with independent filing nations, such as Australia (AU), Canada (CA), New Zealand (NZ), USA (US), and Japan (JP). Securing nation-level patents around the globe will serve as the foundation for commercial opportunities for the Company's pipeline of sublingual products targeting autoimmune diseases such as multiple sclerosis (MS), myasthenia gravis (MG), lupus nephritis (LN) and rheumatoid arthritis (RA).
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Black Iron Congratulates the U.S. and Ukraine on Their Minerals Deal and Aims to Help Pave the Way With Its Highly Advanced Ukraine New Mining Project5.5.2025 07:16:00 CEST | Press release
U.S. and Ukraine entered into a landmark agreement to jointly develop Ukraine's vast mineral resources. Black Iron (TSX:BKI) is developing the most advanced project to construction in Ukraine. Black Iron's successful construction and operation will create a development roadmap for investments under the U.S. - Ukraine Minerals Agreement. TORONTO, ON / ACCESS Newswire / May 5, 2025 / Black Iron Inc. ("Black Iron" or the "Company") (TSX:BKI)(OTCPK:BKIRF)(FWB:BIN) congratulates Ukraine and the United States governments on signing a landmark agreement to jointly develop Ukraine's vast mineral resources - a strategic move designed to accelerate post-war reconstruction and reduce global dependency on hostile-state supply chains. With potentially trillions of dollars worth of untapped mineral resources and growing Western support, Ukraine is positioning itself as a future powerhouse in the critical minerals sector. The challenge is that there hasn't been a new large-scale mine constructed in U
Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards5.5.2025 06:45:00 CEST | Press release
With six newly established, identical BSL-2 laboratories now operational, biologics CDMO Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks VILNIUS, LT / ACCESS Newswire / May 5, 2025 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the expansion of its protein-based and gene therapy service offerings with the addition of Viral Clearance Studies (VCS) capabilities. This strategic growth follows the opening of Northway Biotech's new Gene Therapy Center with dedicated cGMP facilities for virus-related projects. With six newly established, identical BSL-2 laboratories now operational, Northway Biotech can conduct VCS programs for up to six clients simultaneously, significantly alleviating current market bottlenecks. Additionally, the company has expanded its capabilities to perform GMP-compliant manufacturing and testing under BSL-3 condition
Polaris Renewable Energy Announces Q1 2025 Results1.5.2025 07:45:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 1, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three months ended March 31, 2025. This earnings release should be read in conjunction with the Company's condensed consolidated interim financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. 2025 HIGHLIGHTS First quarter consolidated energy production of 216,344 MWh, compared to 213,434 MWh in the first quarter last year. The modest increase is mainly attributable to the production of the Puerto Rican wind farm which was acquired on March 3, 2025 and did not contribute to consolidated energy production during the comparative quarter of 2024. The Company generated $20.3 million in revenue
Polaris Renewable Energy Declares Quarterly Dividend1.5.2025 07:45:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 1, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on May 23rd to shareholders of record at the close of business on May 12th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Company's operations inclu
Sensiba Acquires AssuranceLab to Fuel Innovation in Global Cybersecurity and Risk Assurance30.4.2025 18:00:00 CEST | Press release
SAN RAMON, CA AND SYDNEY, AUSTRALIA / ACCESS Newswire / April 30, 2025 / Sensiba LLP, a Top-75 U.S. accounting and consulting firm, is pleased to announce the acquisition of AssuranceLab Pty. Ltd., a high-growth cybersecurity audit and risk assurance firm headquartered in Australia, with operations across the Americas, APAC, and EMEA. This milestone expands Sensiba's international reach and deepens its security, privacy, and compliance framework capabilities. Together, the combined firm now supports over 2,300 startup and technology-driven enterprise clients worldwide-providing streamlined, high-quality audits across more than 15 compliance standards, including SOC 2, ISO/IEC 27001, HIPAA, CSA STAR, and HITRUST. "We're honored to welcome AssuranceLab to Sensiba. Their reputation in the market is well-earned, driven by innovation, credibility, and a commitment to raising the bar for cybersecurity audits. What makes this such a strong fit is the alignment across our values and client ser
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom